Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults

Trial Profile

A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenzilumab (Primary) ; Remdesivir (Primary)
  • Indications Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms ACTIV-5; ACTIV-5/BET-B; ACTIV-5BET; BET
  • Most Recent Events

    • 12 Jul 2022 Primary endpoint (Occurrence of mechanical ventilation or death at any point through Day 29 in subjects with ordinal scores of 5 or 6 at baseline) has not been met, according to a Humanigen media release.
    • 12 Jul 2022 Preliminary topline results published in the Humanigen Media Release.
    • 30 Jun 2022 According to a Humanigen media release, the company has received a notice from NIH/NIAID that they have cleaned and locked the blinded data in the study. The company expects to receive topline results from NIH/NIAID in July.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top